Drug maker Lupin on Tuesday said it has received approval from the U.S. health regulator to market a generic medication to treat swelling and pain in the eye.
The company has received approval from the U.S. Food and Drug Administration for Bromfenac Ophthalmic Solution, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of Sun Pharma's BromSite Ophthalmic Solution, it added.
Lupin is the exclusive first-to-file for this product, the drug maker said.
ADVERTISEMENT
Shares of Lupin ended 0.43% higher at Rs 1,579.75 apiece on the BSE.
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU
Dr Reddy's ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle
Dr Reddy's, Zydus Recall Drugs In US Over Manufacturing Issues: USFDA
Biocon Unit Gets USFDA Nod For Generic Rifaximin Tablets Used To Treat IBS-D
Alembic Pharma Gets USFDA Nod For Generic Drug To Treat Depression, Anxiety
POPULAR
1
Q2 Results Live: Saregama India Net Profit Down 2.5%, Delhivery, Britannia To Report Results Soon
2
India Unveils AI Governance Framework, Opts For ‘Light-Touch’ Oversight
3
Housing Prices Appreciate 7-19% In Jul-Sep Across Top 8 Cities: PropTiger
4
Navi Mumbai Police Bust Trading Fraud With Links To China, Cambodia; 7 Held
5